A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary) ; Dacarbazine; Doxorubicin; Filgrastim; Filgrastim; Pegfilgrastim; Pegfilgrastim; Vinblastine
Indications Hodgkin's disease
Focus Therapeutic Use
Acronyms S1826; SWOG S1826

17 Apr 2024 Planned End Date changed from 1 Dec 2032 to 1 Apr 2025.
12 Dec 2023 Interim results reporting safety and efficacy data with a median follow-up of over 12 months presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Primary endpoint has not been met (Progression free survival (PFS)) , according to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com